Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.

Front Immunol · 2024 · PMC11194381 · PMID 38915414

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendp=0.075so close (0.05 < p ≤ 0.1)

In a further subgroup analysis, patients with permanent treatment discontinuation due to immune-related toxicity (40/41 were evaluable) showed a trend toward prolonged OS, albeit without statistical significance (p=0.075, Supplementary Figure S2 ). 4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.